Biotechnology

Techseriesinsight > Blog > News > Biotechnology

December 16, 2024
Business Wire
Biotechnology

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that Adcendo ApS (“Adcendo”), a biotech company focused...

December 16, 2024
PRNewswire
Biotechnology

Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), today announced a research collaboration and license agreement to discover next-generation T-cell engagers (“TCEs”)...

December 6, 2024
PRNewswire
Biotechnology

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 2, 2024, the Compensation Committee of IDEAYA’s...

December 6, 2024
PRNewswire
Biotechnology

Another star technology platform of the Sanyou AI-STAL family

With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes...

December 6, 2024
Business Wire
Biotechnology

Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery

Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS™ Full-Length DRUG-seq library preparation technology, which combines, for the first...

December 5, 2024
PRNewswire
Biotechnology

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers...

December 5, 2024
Business Wire
Biotechnology

FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License...

December 4, 2024
Business Wire
Biotechnology

ESYA Labs Partners with Alamar Biosciences to Advance Biomarker Detection and Diagnostics for Neurological Diseases

ESYA Labs, a global leader in lysosomal biology and biomarker discovery for neurodegenerative diseases, has announced a transformative partnership with Alamar Biosciences, a pioneer in ultra-sensitive immunoassay technologies. By...

December 2, 2024
PRNewswire
Biotechnology

Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan

Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. (“Travere”) and currently in phase III clinical trials in Japan, has received Orphan Drug...

November 28, 2024
Business Wire
Biotechnology

Dr. Reddy’s launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of Toripalimab in India....